Loading...
XKRX
008930
Market cap2.43bUSD
Jul 25, Last price  
49,650.00KRW
1D
-0.70%
1Q
75.13%
Jan 2017
-18.74%
Name

Hanmi Science Co Ltd

Chart & Performance

D1W1MN
P/E
56.58
P/S
2.62
EPS
877.54
Div Yield, %
0.20%
Shrs. gr., 5y
-0.29%
Rev. gr., 5y
9.46%
Revenues
1.28t
+2.85%
531,396,197,000606,802,686,000689,962,982,000641,470,958,00016,812,302,74019,645,989,150219,862,566,010532,604,690,900776,215,271,160665,284,666,050652,324,367,920707,995,356,120816,618,823,610857,383,419,140950,164,817,3401,046,054,210,8301,247,906,379,0601,283,432,295,640
Net income
59.42b
-48.38%
52,997,718,00071,551,234,00050,526,894,0005,977,013,000-14,690,506,00012,479,133,0009,578,328,00021,312,164,080178,520,883,2207,937,683,00030,068,972,51018,019,525,57030,741,649,30022,601,096,23042,941,995,98069,209,578,700115,121,512,76059,421,641,040
CFO
82.99b
+136.04%
-16,175,604,00040,923,068,00060,933,793,00036,493,513,000-7,675,597,550-175,636,290-234,788,3005,245,497,90046,927,261,70076,523,442,300-33,681,816,8402,701,370,43013,024,009,77013,817,514,74013,689,812,1009,451,693,03035,158,260,38082,986,394,440
Dividend
Jun 27, 2024100 KRW/sh
Earnings
Jul 28, 2025

Profile

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
IPO date
Jun 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,283,432,296
2.85%
1,247,906,379
19.30%
1,046,054,211
10.09%
Cost of revenue
1,138,026,616
1,089,168,310
1,899,347,870
Unusual Expense (Income)
NOPBT
145,405,680
158,738,069
(853,293,659)
NOPBT Margin
11.33%
12.72%
Operating Taxes
6,401,961
15,421,789
4,144,397
Tax Rate
4.40%
9.72%
NOPAT
139,003,719
143,316,281
(857,438,057)
Net income
59,421,641
-48.38%
115,121,513
66.34%
69,209,579
61.17%
Dividends
(20,324,103)
(13,332,560)
(13,190,733)
Dividend yield
1.04%
0.50%
0.59%
Proceeds from repurchase of equity
(1,930,478)
(7,825,448)
(622,622)
BB yield
0.10%
0.29%
0.03%
Debt
Debt current
216,343,162
202,967,456
195,520,257
Long-term debt
2,784,326
12,146,099
8,809,483
Deferred revenue
2,340,022
2,932,623
8,303,588
Other long-term liabilities
25,227,306
17,311,773
16,594,044
Net debt
(679,412,358)
(555,865,547)
(521,522,289)
Cash flow
Cash from operating activities
82,986,394
35,158,260
9,451,693
CAPEX
(9,832,759)
(8,769,107)
(8,342,387)
Cash from investing activities
(6,873,102)
(18,675,117)
(2,134,913)
Cash from financing activities
(20,388,962)
(10,227,974)
(1,076,010)
FCF
185,421,577
157,093,509
(950,714,016)
Balance
Cash
89,245,843
33,578,959
21,513,397
Long term investments
809,294,003
737,400,143
704,338,632
Excess cash
834,368,232
708,583,783
673,549,318
Stockholders' equity
664,007,613
317,533,413
655,112,390
Invested Capital
419,615,712
703,919,526
291,340,276
ROIC
24.74%
28.80%
ROCE
13.26%
15.35%
EV
Common stock shares outstanding
66,342
67,956
68,494
Price
29,450.00
-24.87%
39,200.00
20.80%
32,450.00
-38.93%
Market cap
1,953,772,636
-26.66%
2,663,867,713
19.85%
2,222,629,229
-39.04%
EV
1,272,135,004
2,107,967,684
1,701,108,717
EBITDA
155,116,289
167,470,449
(847,815,212)
EV/EBITDA
8.20
12.59
Interest
11,345,920
10,160,601
3,689,325
Interest/NOPBT
7.80%
6.40%